NZ333983A - Method of treating sinusitis with uridine triphosphates and related compounds - Google Patents

Method of treating sinusitis with uridine triphosphates and related compounds

Info

Publication number
NZ333983A
NZ333983A NZ333983A NZ33398397A NZ333983A NZ 333983 A NZ333983 A NZ 333983A NZ 333983 A NZ333983 A NZ 333983A NZ 33398397 A NZ33398397 A NZ 33398397A NZ 333983 A NZ333983 A NZ 333983A
Authority
NZ
New Zealand
Prior art keywords
related compounds
treating sinusitis
uridine
uridine triphosphates
adenosine
Prior art date
Application number
NZ333983A
Other languages
English (en)
Inventor
Karla Jacobus
Janet Rideout
Ben Yerxa
William Pendergast
Suhaib Siddiqi
David J Drutz
Original Assignee
Inspire Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inspire Pharmaceuticals Inc filed Critical Inspire Pharmaceuticals Inc
Publication of NZ333983A publication Critical patent/NZ333983A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
NZ333983A 1996-07-03 1997-07-03 Method of treating sinusitis with uridine triphosphates and related compounds NZ333983A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/675,620 US5789391A (en) 1996-07-03 1996-07-03 Method of treating sinusitis with uridine triphosphates and related compounds
PCT/US1997/011795 WO1998003177A1 (en) 1996-07-03 1997-07-03 Method of treating sinusitis with uridine triphosphates and related compounds

Publications (1)

Publication Number Publication Date
NZ333983A true NZ333983A (en) 2000-09-29

Family

ID=24711295

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ333983A NZ333983A (en) 1996-07-03 1997-07-03 Method of treating sinusitis with uridine triphosphates and related compounds

Country Status (9)

Country Link
US (4) US5789391A (enExample)
EP (1) EP0939637A4 (enExample)
JP (1) JP2000514461A (enExample)
KR (1) KR20000067852A (enExample)
CN (1) CN1227491A (enExample)
AU (1) AU728504B2 (enExample)
CA (1) CA2259552A1 (enExample)
NZ (1) NZ333983A (enExample)
WO (1) WO1998003177A1 (enExample)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6423694B1 (en) * 1996-02-21 2002-07-23 Inspire Pharmaceuticals, Inc. Method of treating otitis media with uridine triphosphates and related compounds
US5900407A (en) 1997-02-06 1999-05-04 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with uridine triphosphates and related compounds
US6420347B1 (en) * 1997-03-27 2002-07-16 Inspire Pharmaceuticals, Inc. Method of treating ciliary dyskinesia with uridine triphosphates and related compounds
US6673779B2 (en) * 1996-03-27 2004-01-06 Inspire Pharmaceuticals, Inc. Method of treating ciliary dyskinesia with dinucleoside polyphosphate compounds or UTP analogues
US5968913A (en) * 1996-07-03 1999-10-19 Inspire Pharmaceuticals, Inc. Pharmaceutical compositions of uridine triphosphate
US6319908B1 (en) * 1996-07-03 2001-11-20 Inspire Pharmaceuticals, Inc. Method for large-scale production of di(uridine 5′-tetraphosphate) and salts thereof
US5763447C1 (en) * 1996-07-23 2002-05-07 Inspire Pharmaceuticals Method of preventing or treating pneumonia in immobilized patients with uridine triphosphates and related compounds
US6696425B2 (en) 1997-02-06 2004-02-24 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with purinergic receptor agonists
US6348589B1 (en) * 1997-02-06 2002-02-19 Inspire Pharmaceuticals, Inc. Certain dinucleotides and their use as modulators of mucociliary clearance and ciliary beat frequency
US6921755B2 (en) 1998-02-06 2005-07-26 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with purinergic receptor agonists
US7223744B2 (en) * 1997-02-10 2007-05-29 Inspire Pharmaceuticals, Inc. Pharmaceutical formulation comprising dinucleoside polyphosphates and salts thereof
US6564945B1 (en) * 1997-07-14 2003-05-20 Robert E. Weinstein Medication assemblage for use in sinusitis treatment regimens
NZ501696A (en) * 1997-07-25 2001-08-31 Inspire Pharmaceuticals Inc Method for large-scale production of sodium and ammonium salts of di(uridine 5')-tetraphosphate
US6462028B2 (en) * 1997-07-25 2002-10-08 Inspire Pharmaceuticals, Inc. Method of promoting cervical and vaginal secretions
US6872710B2 (en) * 1997-07-25 2005-03-29 Inspire Pharmaceuticals, Inc. Di(uridine 5′)-tetraphosphate and salts thereof
US6548658B2 (en) * 1997-07-25 2003-04-15 Inspire Pharmaceuticals, Inc. Di-(uridine 5′)-tetraphosphate and salts thereof
TW593331B (en) 1997-07-25 2004-06-21 Inspire Pharmaceuticals Inc Method for large-scale production of di(uridine 5')-tetraphosphate and salts thereof
CN100354296C (zh) * 1998-10-02 2007-12-12 雅玛山酱油株式会社 二尿苷四磷酸或其盐的晶体和其制备方法、以及制备该化合物的方法
WO2000023023A1 (en) * 1998-10-20 2000-04-27 The University Of North Carolina At Chapel Hill Methods of hydrating mucosal surfaces
WO2000039145A1 (en) * 1998-12-23 2000-07-06 The University Of North Carolina At Chapel Hill Targeted gene transfer using g protein coupled receptors
KR20010114214A (ko) * 1999-02-26 2001-12-31 인스파이어 파마슈티컬스 인코퍼레이티드 우리딘, 아데닌 및 시티딘 디포스페이트 및 그의 유사체에의한 점막수화 촉진방법
SE521031C2 (sv) * 1999-05-05 2003-09-23 Srinivas Uppugunduri Nya specifika inhibitorer av akut och kronisk inflammation
US6576224B1 (en) * 1999-07-06 2003-06-10 Sinuspharma, Inc. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
US20020061281A1 (en) * 1999-07-06 2002-05-23 Osbakken Robert S. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
AU2001230533A1 (en) * 2000-02-04 2001-08-14 Kissei Pharmaceutical Co. Ltd. Powdered preparation for inhalation and powder inhalant containing the same packed
US7018985B1 (en) 2000-08-21 2006-03-28 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US7452870B2 (en) * 2000-08-21 2008-11-18 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with P2Y12 receptor antagonist compound
DE10105592A1 (de) 2001-02-06 2002-08-08 Achim Goepferich Platzhalter zur Arzneistofffreigabe in der Stirnhöhle
JP2005508297A (ja) 2001-06-25 2005-03-31 インスパイアー ファーマシューティカルズ，インコーポレイティド Ｐ２ｙプリン受容体作用物質による関節潤滑
EP1409503A1 (en) * 2001-07-25 2004-04-21 Celltech R & D Limited Non-natural carbon-linked nucleotides and dinucleotides
AR037263A1 (es) * 2001-11-06 2004-11-03 Inspire Pharmaceuticals Inc Uso de una formulacion farmaceutica para la manufactura de un medicamento para el tratamiento o prevencion de enfermedades inflamatorias
EP1348466A3 (en) 2002-02-01 2003-10-29 Inspire Pharmaceuticals, Inc. Method for treating pain with adenosine-tetraphosphates
US7179481B2 (en) * 2002-09-19 2007-02-20 Kimberly-Clark Worldwide, Inc. Vaginal health products
US8317816B2 (en) 2002-09-30 2012-11-27 Acclarent, Inc. Balloon catheters and methods for treating paranasal sinuses
US7056889B2 (en) 2002-12-16 2006-06-06 Kimberly-Clark, Worldwide, Inc. Compounds that bind P2Y2 or P2Y1 receptors
US7098189B2 (en) * 2002-12-16 2006-08-29 Kimberly-Clark Worldwide, Inc. Wound and skin care compositions
US7064129B2 (en) 2003-08-18 2006-06-20 Parion Sciences, Inc. Capped pyrazinoylguanidine sodium channel blockers
US8894614B2 (en) 2004-04-21 2014-11-25 Acclarent, Inc. Devices, systems and methods useable for treating frontal sinusitis
US9351750B2 (en) 2004-04-21 2016-05-31 Acclarent, Inc. Devices and methods for treating maxillary sinus disease
US7419497B2 (en) 2004-04-21 2008-09-02 Acclarent, Inc. Methods for treating ethmoid disease
US7720521B2 (en) * 2004-04-21 2010-05-18 Acclarent, Inc. Methods and devices for performing procedures within the ear, nose, throat and paranasal sinuses
US7462175B2 (en) 2004-04-21 2008-12-09 Acclarent, Inc. Devices, systems and methods for treating disorders of the ear, nose and throat
US7654997B2 (en) 2004-04-21 2010-02-02 Acclarent, Inc. Devices, systems and methods for diagnosing and treating sinusitus and other disorders of the ears, nose and/or throat
US20060063973A1 (en) 2004-04-21 2006-03-23 Acclarent, Inc. Methods and apparatus for treating disorders of the ear, nose and throat
US7410480B2 (en) 2004-04-21 2008-08-12 Acclarent, Inc. Devices and methods for delivering therapeutic substances for the treatment of sinusitis and other disorders
US8932276B1 (en) 2004-04-21 2015-01-13 Acclarent, Inc. Shapeable guide catheters and related methods
US20190314620A1 (en) 2004-04-21 2019-10-17 Acclarent, Inc. Apparatus and methods for dilating and modifying ostia of paranasal sinuses and other intranasal or paranasal structures
US7559925B2 (en) 2006-09-15 2009-07-14 Acclarent Inc. Methods and devices for facilitating visualization in a surgical environment
US9554691B2 (en) 2004-04-21 2017-01-31 Acclarent, Inc. Endoscopic methods and devices for transnasal procedures
US9089258B2 (en) 2004-04-21 2015-07-28 Acclarent, Inc. Endoscopic methods and devices for transnasal procedures
US20070167682A1 (en) 2004-04-21 2007-07-19 Acclarent, Inc. Endoscopic methods and devices for transnasal procedures
US8702626B1 (en) 2004-04-21 2014-04-22 Acclarent, Inc. Guidewires for performing image guided procedures
US7361168B2 (en) 2004-04-21 2008-04-22 Acclarent, Inc. Implantable device and methods for delivering drugs and other substances to treat sinusitis and other disorders
US8764729B2 (en) 2004-04-21 2014-07-01 Acclarent, Inc. Frontal sinus spacer
US10188413B1 (en) 2004-04-21 2019-01-29 Acclarent, Inc. Deflectable guide catheters and related methods
US20060004323A1 (en) 2004-04-21 2006-01-05 Exploramed Nc1, Inc. Apparatus and methods for dilating and modifying ostia of paranasal sinuses and other intranasal or paranasal structures
US20070208252A1 (en) 2004-04-21 2007-09-06 Acclarent, Inc. Systems and methods for performing image guided procedures within the ear, nose, throat and paranasal sinuses
US7803150B2 (en) 2004-04-21 2010-09-28 Acclarent, Inc. Devices, systems and methods useable for treating sinusitis
US9101384B2 (en) 2004-04-21 2015-08-11 Acclarent, Inc. Devices, systems and methods for diagnosing and treating sinusitis and other disorders of the ears, Nose and/or throat
US8146400B2 (en) * 2004-04-21 2012-04-03 Acclarent, Inc. Endoscopic methods and devices for transnasal procedures
US8747389B2 (en) 2004-04-21 2014-06-10 Acclarent, Inc. Systems for treating disorders of the ear, nose and throat
US9399121B2 (en) 2004-04-21 2016-07-26 Acclarent, Inc. Systems and methods for transnasal dilation of passageways in the ear, nose or throat
US7485666B2 (en) * 2004-06-17 2009-02-03 Kimberly-Clark Worldwide, Inc. Vaginal health products
US8951225B2 (en) 2005-06-10 2015-02-10 Acclarent, Inc. Catheters with non-removable guide members useable for treatment of sinusitis
US7368439B2 (en) * 2005-06-15 2008-05-06 Bar - Ilan University Dinucleoside poly(borano)phosphate derivatives and uses thereof
US8114113B2 (en) 2005-09-23 2012-02-14 Acclarent, Inc. Multi-conduit balloon catheter
EP2036567A3 (en) 2005-12-06 2009-12-09 P2-Science APS Modulation of the P2Y2 receptor pathway
US20070173463A1 (en) * 2006-01-20 2007-07-26 Brechtelsbauer Paul B Method and composition for treating otitis media
US20070249556A1 (en) * 2006-04-21 2007-10-25 Brubaker Kurt E Method of treating inflammation
US8190389B2 (en) 2006-05-17 2012-05-29 Acclarent, Inc. Adapter for attaching electromagnetic image guidance components to a medical device
US9820688B2 (en) * 2006-09-15 2017-11-21 Acclarent, Inc. Sinus illumination lightwire device
US8439687B1 (en) 2006-12-29 2013-05-14 Acclarent, Inc. Apparatus and method for simulated insertion and positioning of guidewares and other interventional devices
WO2008124787A2 (en) 2007-04-09 2008-10-16 Acclarent, Inc. Ethmoidotomy system and implantable spacer devices having therapeutic substance delivery capability for treatment of paranasal sinusitis
US8118757B2 (en) * 2007-04-30 2012-02-21 Acclarent, Inc. Methods and devices for ostium measurement
US8485199B2 (en) 2007-05-08 2013-07-16 Acclarent, Inc. Methods and devices for protecting nasal turbinate during surgery
US10206821B2 (en) 2007-12-20 2019-02-19 Acclarent, Inc. Eustachian tube dilation balloon with ventilation path
MX344703B (es) 2008-02-26 2017-01-03 Parion Sciences Inc Bloqueadores de canal de sodio poliaromaticos.
US8182432B2 (en) 2008-03-10 2012-05-22 Acclarent, Inc. Corewire design and construction for medical devices
KR101653180B1 (ko) 2008-07-30 2016-09-01 아클라런트, 인코포레이션 부비 개구 탐지기 장치 및 방법
CA2737804A1 (en) 2008-09-18 2010-03-25 Acclarent, Inc. Methods and apparatus for treating disorders of the ear nose and throat
US20100241155A1 (en) 2009-03-20 2010-09-23 Acclarent, Inc. Guide system with suction
US7978742B1 (en) 2010-03-24 2011-07-12 Corning Incorporated Methods for operating diode lasers
US8435290B2 (en) 2009-03-31 2013-05-07 Acclarent, Inc. System and method for treatment of non-ventilating middle ear by providing a gas pathway through the nasopharynx
US8394355B2 (en) 2009-08-10 2013-03-12 P2 Science Aps Use of UTP for the diagnosis of stenoses and other conditions of restricted blood flow
US9155492B2 (en) 2010-09-24 2015-10-13 Acclarent, Inc. Sinus illumination lightwire device
BR112013032771B1 (pt) 2011-06-27 2021-01-12 Parion Sciences, Inc. dipeptídio quimicamente e metabolicamente estável possuindo potente atividade bloqueadora de canais de sódio
US9433437B2 (en) 2013-03-15 2016-09-06 Acclarent, Inc. Apparatus and method for treatment of ethmoid sinusitis
US9629684B2 (en) 2013-03-15 2017-04-25 Acclarent, Inc. Apparatus and method for treatment of ethmoid sinusitis
US20180125876A1 (en) 2015-05-20 2018-05-10 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and Pharmaceutical Composition for Modulation Polarization and Activation of Macrophages
EP3919062A1 (en) 2020-06-02 2021-12-08 Institut Gustave-Roussy Modulators of purinergic receptors and related immune checkpoint for treating acute respiratory distress syndrom
WO2021245107A2 (en) 2020-06-02 2021-12-09 Institut Gustave Roussy Modulators of purinergic receptors and related immune checkpoint for treating acute respiratory distress syndrom

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9027968D0 (en) * 1990-12-22 1991-02-13 Fisons Plc Method of treatment
EP0517573A1 (fr) * 1991-06-05 1992-12-09 Synthelabo Compositions pharmaceutiques pour le traitement des affections des voies respiratoires
FR2677250B1 (fr) * 1991-06-05 1995-01-20 Synthelabo Compositions pharmaceutiques contenant de l'adenosine-5-triphosphate disodique.
FR2684299B1 (fr) * 1991-12-02 1995-03-24 Synthelabo Compositions pharmaceutiques contenant de l'adenosine-5-triphosphate disodique et de l'amiloride.
US5292498A (en) * 1991-06-19 1994-03-08 The University Of North Carolina At Chapel Hill Method of treating lung disease with uridine triphosphates
US5635160A (en) * 1995-06-07 1997-06-03 The University Of North Carolina At Chapel Hill Dinucleotides useful for the treatment of cystic fibrosis and for hydrating mucus secretions
NZ332426A (en) * 1996-03-27 2000-09-29 Univ North Carolina Method of treating diseases involving dysfunction of ciliary movement such as ciliary dyskinesia and infertility with uridine triphosphates (UTP) and related compounds

Also Published As

Publication number Publication date
EP0939637A4 (en) 2001-09-26
CN1227491A (zh) 1999-09-01
US5972904A (en) 1999-10-26
JP2000514461A (ja) 2000-10-31
CA2259552A1 (en) 1998-01-29
WO1998003177A1 (en) 1998-01-29
AU728504B2 (en) 2001-01-11
EP0939637A1 (en) 1999-09-08
KR20000067852A (ko) 2000-11-25
AU4408997A (en) 1998-02-10
US5981506A (en) 1999-11-09
US5958897A (en) 1999-09-28
US5789391A (en) 1998-08-04

Similar Documents

Publication Publication Date Title
NZ333983A (en) Method of treating sinusitis with uridine triphosphates and related compounds
WO2000030629A3 (en) Method of promoting cervical and vaginal secretions
EP1121371B8 (en) Nucleotide compounds including a rigid linker
US6140496A (en) Precursors for deoxyribonucleotides containing non-standard nucleosides
US3817982A (en) 2{40 ,3{40 -unsaturated nucleosides and method of making
ATE196912T1 (de) Propargylethoxyamino nucleotide
WO2003072757A9 (en) Nucleotide mimics and their prodrugs
NZ507913A (en) Novel nucleosides having bicyclic sugar moiety
KR890008161A (ko) 2',3'-디데옥시-2'-플루오로뉴클레오사이드류
TW341574B (en) METHOD AND COMPOSITIONS FOR THE SYNTHESIS OF DIOXOLANE NUCLEOSIDES WITH β-CONFIGURATION the invention relates to methods and compositions for preparing biologically important nucleoside analogues containing 1,3-dioxolane sugar rings.
ATE150487T1 (de) Verfahren zur herstellung von cytidin-diphosphat- cholin
AU5831590A (en) 2-halo-9-(2-deoxy-2-fluoro-b-d-arabinofuranosyl) adenine nucleoside derivatives
Bloch The design of biologically active nucleosides
Plagemann et al. Permeation and salvage of dideoxyadenosine in mammalian cells.
Hutchinson New approaches to the synthesis of antiviral nucleosides
EP0081099A2 (en) Capped oligonucleotide anti-viral agents
Cook et al. New class of potent guanine antimetabolites. Synthesis of 3-deazaguanine, 3-deazaguanosine, and 3-deazaguanylic acid by a novel ring closure of imidazole precursors
Kierdaszuk et al. Substrate/inhibitor properties of human deoxycytidine kinase (dCK) and thymidine kinases (TK1 and TK2) towards the sugar moiety of nucleosides, including O′-alkyl analogues
CA2046865A1 (en) Inosine-guanosine kinase
US3804827A (en) 1-beta-d-arabinofuranosylcytosine-3',5'-cyclic phosphate and derivatives thereof
KR960701639A (ko) 심기능 회복제(heart function restorative)
WO2019195494A1 (en) Compositions and methods for synthesis of phosphorylated molecules
RU2183213C2 (ru) Модифицированные нуклеозид-5'-трифосфаты как антивирусные агенты
ATE284894T1 (de) L-pyranosyl-nukleoside
EP1138775A3 (en) Method of preparing a guanosine-group compound and an intermediate thereof

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)